Year |
Citation |
Score |
2019 |
Hannouf MB, Zaric GS, Blanchette P, Brezden-Masley C, Paulden M, McCabe C, Raphael J, Brackstone M. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. The Pharmacogenomics Journal. PMID 31130722 DOI: 10.1038/S41397-019-0089-X |
0.348 |
|
2019 |
Qu M, Chen Y, Zaric G, Senan S, Olson R, Harrow S, John-Baptiste A, Gaede S, Mulroy L, Schellenberg D, Senthi S, Swaminath A, Kopek N, Liu M, Warner A, et al. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-Comet International Journal of Radiation Oncology*Biology*Physics. 105: S100-S101. DOI: 10.1016/S0167-8140(19)33384-5 |
0.354 |
|
2018 |
Hannouf M, Zaric G, Brackstone M. Abstract P4-12-05: Cost-effectiveness analysis of second-generation multi-gene expression prognostic assays compared with the standard 21-gene recurrence score assay to guide adjuvant therapy decisions in women with early stage breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-12-05 |
0.335 |
|
2017 |
Mahjoub R, Ødegaard F, Zaric GS. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success. Health Economics. PMID 28627808 DOI: 10.1002/Hec.3522 |
0.32 |
|
2017 |
Ghamat S, Zaric GS, Pun H. Contracts to Promote Optimal Use of Optional Diagnostic Tests in Cancer Treatment Production and Operations Management. 27: 2184-2200. DOI: 10.1111/Poms.12780 |
0.317 |
|
2016 |
Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan P, Hoch JS, Zaric GS. Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary. The Pharmacogenomics Journal. PMID 27019982 DOI: 10.1038/Tpj.2015.94 |
0.368 |
|
2016 |
Zaric GS. Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine. Pharmacoeconomics. PMID 26899833 DOI: 10.1007/S40273-016-0388-X |
0.385 |
|
2015 |
Nguyen TK, Goodman CD, Boldt RG, Warner A, Palma DA, Rodrigues GB, Lock MI, Mishra MV, Zaric GS, Louie AV. Evaluation of Health Economics in Radiation Oncology: A Systematic Review. International Journal of Radiation Oncology, Biology, Physics. PMID 26883562 DOI: 10.1016/j.ijrobp.2015.12.359 |
0.323 |
|
2015 |
Enns EA, Zaric GS, Strike CJ, Jairam JA, Kolla G, Bayoumi AM. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada. Addiction (Abingdon, England). PMID 26616368 DOI: 10.1111/Add.13195 |
0.334 |
|
2015 |
Zhang H, Zaric GS. Using price-volume agreements to manage pharmaceutical leakage and off-label promotion. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. 16: 747-61. PMID 25193525 DOI: 10.1007/S10198-014-0626-0 |
0.308 |
|
2013 |
Fournier DL, Zaric GS. Simulating neonatal intensive care capacity in British Columbia Socio-Economic Planning Sciences. 47: 131-141. DOI: 10.1016/J.Seps.2013.01.001 |
0.312 |
|
2012 |
Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. Plos One. 7: e45176. PMID 23028828 DOI: 10.1371/Journal.Pone.0045176 |
0.606 |
|
2012 |
Zaric GS, Brennan AW, Varenbut M, Daiter JM. The cost of providing methadone maintenance treatment in Ontario, Canada. The American Journal of Drug and Alcohol Abuse. 38: 559-66. PMID 22783917 DOI: 10.3109/00952990.2012.694518 |
0.362 |
|
2012 |
Zecevic AA, Chesworth BM, Zaric GS, Huang Q, Salmon A, McAuslan D, Welch R, Brunton D. Estimating the cost of serious injurious falls in a Canadian acute care hospital. Canadian Journal On Aging = La Revue Canadienne Du Vieillissement. 31: 139-47. PMID 22621825 DOI: 10.1017/S0714980812000037 |
0.334 |
|
2012 |
Cao JQ, Rodrigues GB, Louie AV, Zaric GS. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules. Clinical Lung Cancer. 13: 161-70. PMID 22133290 DOI: 10.1016/J.Cllc.2011.09.002 |
0.377 |
|
2012 |
Cipriano LE, Levesque BG, Zaric GS, Loftus EV, Sandborn WJ. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflammatory Bowel Diseases. 18: 1240-8. PMID 21928375 DOI: 10.1002/Ibd.21862 |
0.303 |
|
2011 |
Malvankar MM, Zaric GS. Incentives for Optimal Multi-level Allocation of HIV Prevention Resources. Infor. 49: 241-246. PMID 23766551 DOI: 10.3138/Infor.49.4.241 |
0.358 |
|
2011 |
Lasry A, Carter MW, Zaric GS. Allocating funds for HIV/AIDS: a descriptive study of KwaDukuza, South Africa. Health Policy and Planning. 26: 33-42. PMID 20551138 DOI: 10.1093/Heapol/Czq022 |
0.336 |
|
2011 |
Levesque BG, Cipriano LE, Zaric G, Sandborn WJ, Loftus EV. Cost-Effectiveness of Computed Tomographic Enterography Compared to Magnetic Resonance Enterography in a Simulated Medicare Population With Crohn's Disease Gastroenterology. 140: S-693. DOI: 10.1016/S0016-5085(11)62875-8 |
0.357 |
|
2010 |
Cipriano LE, Barth W, Zaric GS. The cost-effectiveness of targeted or universal screening for vasa praevia at 18-20 weeks of gestation in Ontario Bjog: An International Journal of Obstetrics and Gynaecology. 117: 1108-1118. PMID 20560948 DOI: 10.1111/J.1471-0528.2010.02621.X |
0.355 |
|
2009 |
Brandeau ML, Zaric GS. Optimal investment in HIV prevention programs: more is not always better. Health Care Management Science. 12: 27-37. PMID 19938440 DOI: 10.1007/S10729-008-9074-7 |
0.618 |
|
2009 |
Zaric GS, Xie B. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 838-45. PMID 19490563 DOI: 10.1111/J.1524-4733.2009.00510.X |
0.344 |
|
2008 |
Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 179: 1143-51. PMID 19015565 DOI: 10.1503/Cmaj.080808 |
0.403 |
|
2008 |
Brandeau ML, Zaric GS, Freiesleben J, Edwards FL, Bravata DM. An ounce of prevention is worth a pound of cure: improving communication to reduce mortality during bioterrorism responses. American Journal of Disaster Medicine. 3: 65-78. PMID 18522248 DOI: 10.5055/Ajdm.2008.0010 |
0.522 |
|
2008 |
Lasry A, Carter MW, Zaric GS. S4HARA: System for HIV/AIDS resource allocation. Cost Effectiveness and Resource Allocation : C/E. 6: 7. PMID 18366800 DOI: 10.1186/1478-7547-6-7 |
0.346 |
|
2008 |
Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 28: 359-76. PMID 18349433 DOI: 10.1177/0272989X07312714 |
0.604 |
|
2008 |
Zaric GS, Bravata DM, Cleophas Holty JE, McDonald KM, Owens DK, Brandeau ML. Modeling the logistics of response to anthrax bioterrorism. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 28: 332-50. PMID 18349432 DOI: 10.1177/0272989X07312721 |
0.533 |
|
2008 |
Zaric GS. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression. Health Economics. 17: 1277-94. PMID 18186544 DOI: 10.1002/Hec.1332 |
0.335 |
|
2008 |
Cipriano L, Barth W, Zaric G. PIH10 THE COST-EFFECTIVENESS OF ROUTINE SCREENING FOR VASA PREVIA AT 18-20 WEEKS GESTATION IN ONTARIO Value in Health. 11: A248. DOI: 10.1016/S1098-3015(10)70784-1 |
0.34 |
|
2007 |
Zaric GS, Brandeau ML. A little planning goes a long way: multilevel allocation of HIV prevention resources. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 27: 71-81. PMID 17237455 DOI: 10.1177/0272989X06297395 |
0.593 |
|
2007 |
Lasry A, Zaric GS, Carter MW. Multi-level resource allocation for HIV prevention: A model for developing countries European Journal of Operational Research. 180: 786-799. DOI: 10.1016/J.Ejor.2006.02.043 |
0.359 |
|
2006 |
Bravata DM, Zaric GS, Holty JE, Brandeau ML, Wilhelm ER, McDonald KM, Owens DK. Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies. Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science. 4: 244-62. PMID 16999586 DOI: 10.1089/Bsp.2006.4.244 |
0.572 |
|
2006 |
Zaric GS, Hoch JS. Medical savings accounts: opportunities for cost savings? International Transactions in Operational Research. 13: 493-513. DOI: 10.1111/J.1475-3995.2006.00560.X |
0.396 |
|
2005 |
Brandeau ML, Zaric GS, de Angelis V. Improved allocation of HIV prevention resources: using information about prevention program production functions. Health Care Management Science. 8: 19-28. PMID 15782509 DOI: 10.1007/S10729-005-5213-6 |
0.631 |
|
2005 |
Zaric GS, O'brien BJ. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget. Health Economics. 14: 793-803. PMID 15685669 DOI: 10.1002/Hec.976 |
0.35 |
|
2004 |
Bravata DM, McDonald KM, Owens DK, Wilhelm ER, Brandeau ML, Zaric GS, Holty JE, Liu H, Sundaram V. Regionalization of bioterrorism preparedness and response. Evidence Report/Technology Assessment (Summary). 1-7. PMID 15133889 |
0.452 |
|
2003 |
Zaric GS. The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysis. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 23: 379-96. PMID 14570296 DOI: 10.1177/0272989X03256883 |
0.404 |
|
2003 |
Brandeau ML, Zaric GS, Richter A. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis. Journal of Health Economics. 22: 575-98. PMID 12842316 DOI: 10.1016/S0167-6296(03)00043-2 |
0.741 |
|
2003 |
Zaric G, Bayoumi A, Brandeau M, Owens D. PIN40: THE COST EFFECTIVENESS OF IMPROVED ADHERENCE TO ANTIRETROVIRAL TREATMENT Value in Health. 6: 266. DOI: 10.1016/S1098-3015(10)64017-X |
0.609 |
|
2002 |
Zaric GS, Brandeau ML. Dynamic resource allocation for epidemic control in multiple populations. Ima Journal of Mathematics Applied in Medicine and Biology. 19: 235-55. PMID 12828363 DOI: 10.1093/Imammb/19.4.235 |
0.581 |
|
2001 |
Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction (Abingdon, England). 96: 1267-78. PMID 11672491 DOI: 10.1046/J.1360-0443.2001.96912676.X |
0.61 |
|
2001 |
Zaric GS, Brandeau ML. Optimal investment in a portfolio of HIV prevention programs. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 21: 391-408. PMID 11575489 DOI: 10.1177/0272989X0102100506 |
0.605 |
|
2001 |
Zaric GS, Brandeau ML. Resource allocation for epidemic control over short time horizons. Mathematical Biosciences. 171: 33-58. PMID 11325383 DOI: 10.1016/S0025-5564(01)00050-5 |
0.571 |
|
2000 |
Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. Journal of Acquired Immune Deficiency Syndromes (1999). 25: 403-16. PMID 11141240 DOI: 10.1097/00042560-200012150-00004 |
0.61 |
|
2000 |
Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. American Journal of Public Health. 90: 1100-11. PMID 10897189 DOI: 10.2105/Ajph.90.7.1100 |
0.632 |
|
2000 |
Zaric GS, Brandeau ML, Barnett PG. Methadone maintenance and HIV prevention: a cost-effectiveness analysis Management Science. 46: 1013-1031. DOI: 10.1287/Mnsc.46.8.1013.12025 |
0.653 |
|
1998 |
Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The Effects of Protease Inhibitors on the Spread of HIV and the Development of Drug-Resistant HIV Strains: A Simulation Study Simulation. 71: 262-275. |
0.524 |
|
Show low-probability matches. |